Epigenetically inactivated RASSF1A as a tumor biomarker

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• RASSF1A, a tumor suppressor gene, is frequently inactivated in various cancers via promoter hypermethylation.
• Epigenetic inactivation of RASSF1A is a key area of research for cancer biomarkers.
• Traditional analysis involves genomic DNA (gDNA), but cell-free DNA (cfDNA) from liquid biopsies offers a novel approach.

Purpose of the Study:

• To review the evidence on aberrant RASSF1A methylation in both gDNA and cfDNA across different cancer types.
• To evaluate the utility of RASSF1A methylation as a biomarker for early cancer diagnosis, prognosis, and surveillance.
• To compare the methylation frequencies and discuss the strengths and weaknesses of RASSF1A analysis in gDNA versus cfDNA.

Main Methods:

• Literature review of studies analyzing RASSF1A promoter methylation.
• Comparison of RASSF1A methylation frequencies in genomic DNA (gDNA) and cell-free DNA (cfDNA).
• Discussion of analytical methods, strengths, and limitations for both gDNA and cfDNA analyses.

Main Results:

• Aberrantly methylated RASSF1A is detected in gDNA and cfDNA across various cancer types.
• RASSF1A methylation in cfDNA shows potential for early cancer detection and monitoring.
• Methylation frequencies and detection rates vary between gDNA and cfDNA analyses and cancer types.

Conclusions:

• RASSF1A promoter methylation is a significant epigenetic event in cancer, recognized in diagnostic panels.
• While promising, the diagnostic utility of RASSF1A methylation, particularly in cfDNA, remains largely experimental.
• Further research is needed to fully establish RASSF1A methylation as a reliable biomarker for clinical application.